High Homocysteine: What It Means and What Actually Lowers It

If a blood test just came back with a high homocysteine result, you are probably holding two questions at once: what does this number mean, and what should I do about it. The short answer most people hear is to take B vitamins. The more useful answer starts with a different question: why is your homocysteine high in the first place.

What Homocysteine Actually Is

Homocysteine is a sulfur-containing amino acid your body makes from methionine, an amino acid you get from protein. Every time your body uses methionine to donate a methyl group, homocysteine is what is left behind.

That leftover sits at a crossroads, and your body has several ways to move it along.

• The folate route. Folate (vitamin B9) becomes 5-MTHF, and the MTHFR enzyme helps convert it into the form that hands a methyl group to homocysteine.
• The B12 route. Vitamin B12 is the cofactor for methionine synthase, the enzyme that turns homocysteine back into methionine. Without enough B12, this road is closed.
• The B6 route. Vitamin B6-dependent cystathionine beta-synthase sends homocysteine toward cysteine instead.
• The betaine route. Betaine (trimethylglycine, or TMG) donates a methyl group directly through an enzyme called BHMT, bypassing the folate and B12 steps.

This is why homocysteine is a useful marker. It sits downstream of several systems, so a rise tells you one route is not working as it should. Kumar and colleagues described in a 2017 review what pushes it up: enzyme defects, a shortage of B6, B12 or folate, and methionine-rich diets. Those routes live in the detox and methylation pathway.

Why a Higher Number Gets Attention

A 2002 meta-analysis by Wald and colleagues combined 72 genetic studies covering 16,849 cases with 20 prospective studies covering 3,820 participants. For every 5 µmol/L higher homocysteine, the odds of ischemic heart disease were 1.42 (95% CI 1.11 to 1.84) in the genetic studies and 1.32 (1.19 to 1.45) in the prospective ones. For stroke, the odds were 1.65 (0.66 to 4.13) in the genetic studies and 1.59 (1.29 to 1.96) in the prospective ones.

Two very different study designs, with different sources of error, gave similar answers, which is why researchers argued the relationship might be causal. It is also why heart and circulation research keeps returning to this marker.

A second 2002 meta-analysis, from the Homocysteine Studies Collaboration, looked at 30 studies covering 5,073 ischemic heart disease events and 1,113 stroke events. It found the associations were stronger in retrospective studies, where blood was drawn after disease onset, than in prospective ones. That is the classic warning sign for reverse causation: early disease can change a marker rather than the other way around. A companion analysis by Klerk and colleagues used the MTHFR 677C>T variant, which raises homocysteine, as a natural experiment.

What counts as "normal" depends on the lab that ran your test. Reference intervals differ between laboratories, and the interval printed on your own report is the one that applies to you. There is no single universal cutoff, and risk rises continuously across the range rather than jumping at a hard line.

The Trials That Tested the Idea

Association is not the same as cause. So researchers ran large randomized trials, lowered homocysteine with B vitamins, and watched whether outcomes improved. They did not.

• NORVIT followed 3,749 men and women after a first heart attack for a median of 40 months. Folic acid plus B12 lowered homocysteine 27%. The primary composite endpoint was a relative risk of 1.08 (95% CI 0.93 to 1.25; P=0.31). The arm taking folic acid, B12 and B6 together trended toward increased risk at 1.22 (1.00 to 1.50; P=0.05). The authors wrote that such treatment "should therefore not be recommended."
• HOPE-2 followed 5,522 people aged 55 and older with vascular disease or diabetes for a mean of five years. Homocysteine fell 2.4 µmol/L in the active arm and rose 0.8 µmol/L on placebo. The primary outcome was 0.95 (0.84 to 1.07; P=0.41). Stroke was 0.75 (0.59 to 0.97) in a secondary analysis, but hospitalizations for unstable angina were higher in the active arm, at 1.24 (1.04 to 1.49).
• WAFACS followed 5,442 women at high risk for cardiovascular disease for 7.3 years. The primary composite endpoint was 1.03 (0.90 to 1.19; P=0.65).
• VISP enrolled 3,680 adults who had already had a nondisabling stroke. It compared high-dose against low-dose B vitamins rather than against placebo, and the higher dose did not reduce recurrent stroke.

Then came the meta-analysis that pulled it together. Clarke and colleagues pooled 8 randomized trials covering 37,485 people in 2010. Folic acid produced an average 25% reduction in homocysteine. Major vascular events came out at 1.01 (0.97 to 1.05), major coronary events at 1.03 (0.97 to 1.10), and stroke at 0.96 (0.87 to 1.06). There was no significant effect in any subgroup.

So Why Did the Trials Fail?

The best explanation involves background folate status, and it comes from a clever study design. A person's genotype is set at birth and cannot be changed by disease, so it works as a natural experiment: if homocysteine truly causes cardiovascular events, people carrying the MTHFR 677C>T variant should have more of them.

Holmes and colleagues tested that across 237 datasets in 2011, covering 59,995 people with homocysteine measurements and 20,885 stroke events. They also pooled 13 randomized trials of homocysteine lowering, covering 45,549 people and 2,314 stroke events.

In low-folate regions, mainly Asia, people with the TT genotype had homocysteine 3.12 µmol/L higher than those with the CC genotype (95% CI 2.23 to 4.01), and their stroke odds were 1.68 (1.44 to 1.97). In folate-fortified regions, including America, Australia and New Zealand, the same genotype moved homocysteine by only 0.13 µmol/L (95% CI -0.85 to 1.11), and stroke odds were 1.03 (0.84 to 1.25).

The trial evidence matched. Across the 13 trials, the summary relative risk of stroke was 0.94 (0.85 to 1.04), and the genetic studies predicted 1.00 (0.90 to 1.11) for the same homocysteine reduction in similarly folate-replete populations. The two lines of evidence agreed: no meaningful benefit. In low-folate regions the genetic data predicted a larger benefit of 0.78 (0.68 to 0.90), but no trial had yet tested homocysteine lowering exclusively in a low-folate region.

Why are the US, Canada and much of Europe folate-replete? Folic acid fortification of grain began in the US in 1998. Holmes and colleagues described the consequence directly: in fortified regions, the same genotype barely moved homocysteine at all, which is what you would expect if most people there already had enough folate for the enzyme to do its job. The trials that found no benefit were run against exactly that backdrop. Morris and colleagues showed in 2007 how tangled this gets in older adults, where folate status and B12 status interact rather than acting independently.

Two Trials That Did Show Something

• Wang and colleagues (2007) pooled 8 randomized trials and found folic acid reduced stroke risk by 18%, a relative risk of 0.82 (0.68 to 1.00; p=0.045). The benefit was larger where treatment lasted more than 36 months (0.71, 0.57 to 0.87), where homocysteine fell more than 20% (0.77, 0.63 to 0.94), where there was no or only partial grain fortification (0.75, 0.62 to 0.91), and where there was no history of stroke (0.75, 0.62 to 0.90).
• CSPPT (2015) randomized 20,702 Chinese adults with hypertension and no history of stroke or heart attack to enalapril with folic acid 0.8 mg or enalapril alone, for a median of 4.5 years. First stroke occurred in 2.7% of the folic acid group versus 3.4% of controls, a hazard ratio of 0.79 (95% CI 0.68 to 0.93). That trial ran in a population without grain fortification.

The honest reading is not "B vitamins do not work." It is that whether lowering homocysteine helps appears to depend on whether the population was already folate-replete before the trial started.

Why Is Your Homocysteine High? The Real Causes

If the useful question is why rather than how much, here is the list to work through.

1. Low vitamin B12. B12 is the cofactor at methionine synthase, and a genuine deficiency is a treatable cause of elevated homocysteine, as Stabler describes in a 2013 clinical review. This is usually the first thing to assess.
2. Low folate. Folate is the methyl donor upstream of the whole cycle.
3. Reduced kidney clearance. Your kidneys clear homocysteine, so when kidney function declines, homocysteine tends to rise. That is a clearance problem, not a vitamin problem.
4. Alcohol. Alcohol intake goes with higher homocysteine.
5. Certain medications. Kumar's 2017 review notes that some lipid-lowering and anti-Parkinsonian drugs raise homocysteine.
6. Genetics. The MTHFR 677C>T variant raises homocysteine, but how much it matters depends heavily on folate status.

These are not the same problem wearing different labels. A B12 deficiency and a kidney clearance issue can produce an identical homocysteine number while calling for completely different conversations with your clinician.

If genotype is part of your picture, the MTHFR and methylation guide covers what the variants do and do not change. If B12 status is the open question, the comparison of vitamin B12 forms covers how the forms differ.

Betaine (TMG): A Different Route

Betaine, also called trimethylglycine or TMG, is a methyl donor that works through the BHMT enzyme. It lets homocysteine convert back to methionine without going through the folate and B12 steps at all.

Steenge and colleagues ran a six-week study in people with mildly elevated homocysteine, comparing 6 g per day of betaine, 800 µg per day of folic acid, and placebo in groups of 12. Fasting homocysteine fell 1.8 µmol/L on betaine (95% CI -3.6 to 0.0) against a 0.5 µmol/L rise on placebo. Folic acid produced a larger fasting drop of 2.7 µmol/L (-4.5 to -0.9). The betaine confidence interval touches zero, which is a real limitation of that result.

The more striking finding was what happened after a methionine load. Betaine cut the post-load homocysteine AUC by 221 µmol·24h/L (95% CI -425 to -16). Folic acid had no effect on the post-load response at all. Betaine and folate act on genuinely different parts of the curve.

Olthof and colleagues then mapped the dose. In four groups of 19 healthy subjects over six weeks, fasting homocysteine ended up 12% (P<0.01), 15% (P<0.002) and 20% (P<0.0001) lower than placebo at 1.5 g, 3 g and 6 g per day. The post-methionine-load rise was 23%, 30% and 40% lower at those same doses, so the effect scaled with dose and showed up well below the 6 g used in the earlier study.

Allergy Research Group, TMG Trimethylglycine 100 VegiCaps is betaine in capsule form.

Homocysteine and the Brain: One Real Signal, One Null Result

VITACOG, published by Smith and colleagues in 2010, enrolled 271 people over 70 with mild cognitive impairment. Of those, 168 completed serial MRI scans over 24 months. Brain atrophy ran at 0.76% per year (95% CI 0.63 to 0.90) in the active group versus 1.08% per year (0.94 to 1.22) on placebo, with P=0.001. The treatment response was related to baseline homocysteine level, so people who started higher responded more.

That is a real, statistically robust finding. It is also half the story. Clarke and colleagues published a meta-analysis in 2014 pooling 11 trials with cognitive data on roughly 22,000 people. In the four trials that reported full cognitive domains, B vitamins lowered homocysteine by 28%. There was no significant effect on any cognitive domain z score, and no effect on global cognitive function.

Both results can be true at once. Slower brain shrinkage on an MRI is not the same as a measurable improvement in how well someone thinks, at least not over the time frames these trials covered. The brain and memory hub collects the wider context this finding sits inside.

What to Test, and What to Ask Your Clinician

A high homocysteine result is a starting point, not a verdict.

1. Get the actual number and your lab's reference interval. Ranges differ between laboratories, and the one on your report is the one that applies to you.
2. Test B12 and folate status directly. Do not assume a homocysteine problem is a B vitamin problem without measuring them.
3. Check kidney function. Markers such as creatinine and eGFR show whether clearance is part of the picture.
4. Review your medications and alcohol intake with your clinician or pharmacist.
5. Ask about riboflavin if you carry the MTHFR 677TT genotype. Riboflavin is the FAD cofactor for MTHFR. Wilson and colleagues identified 157 people with the TT genotype out of 1,427 patients with hypertension, and 91 entered a trial of riboflavin 1.6 mg per day for 16 weeks. A four-year follow-up by the same group supported the same genotype-specific effect. This is targeted, not general: it applies to that genotype, not to everyone with a high homocysteine.

Integrative Therapeutics, Riboflavin 30 Tablets is a standalone riboflavin option of the kind that genotype-specific conversation can involve.

The most important question to bring to your clinician is not "how do I lower this number" but "why is it high, and what does that tell us about what to do next."

Agape Nutrition carries practitioner-grade methylation and B-vitamin formulas from several manufacturers, and every product on the site is held to the same quality bar. To see what is actually in a bottle before you buy it, the third-party testing page explains how that verification works.

The Bottom Line

• Homocysteine is a real, reproducible risk marker, across both genetic and prospective study designs.
• Lowering it with B vitamins did not reduce heart attacks, strokes or deaths in the large trials run in the US, Canada and Europe.
• The best explanation is background folate status: in fortified populations the genotype barely moves homocysteine and trials run there found no benefit.
• Betaine lowers homocysteine through a different route and blunts the post-methionine-load rise especially well.
• The brain data is mixed: slower atrophy on MRI, no measurable cognitive gain across trials.

The question worth asking is not how to push the number down. It is why it is high, and which of the several possible causes is actually yours.

What We Recommend

Protocols For Health, Methylation Minerals 30 Capsules

A first-party Protocols For Health formula for methylation support, and the lowest-priced option here.

$21.99

XYMOGEN, Methyl Protect 120 Capsules

A practitioner-grade XYMOGEN formula for methylation support, in a 120-capsule supply that suits ongoing use rather than a short trial.

$74.99

XYMOGEN, 5-MTHF Plus B12 Cherry 60 Tablets

Pairs 5-MTHF with B12, the two nutrients central to methylation.

$41.99

Allergy Research Group, Homocysteine Plus 90 Veg Capsules

A newer Agape listing from Allergy Research Group, in a 90-capsule supply.

$27.39

References

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202. https://pubmed.ncbi.nlm.nih.gov/12446535/
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288(16):2015-22. https://pubmed.ncbi.nlm.nih.gov/12387654/
3. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C>T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288(16):2023-31. https://pubmed.ncbi.nlm.nih.gov/12387655/
4. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-88. https://pubmed.ncbi.nlm.nih.gov/16531614/
5. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-77. https://pubmed.ncbi.nlm.nih.gov/16531613/
6. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027-36. https://pubmed.ncbi.nlm.nih.gov/18460663/
7. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-75. https://pubmed.ncbi.nlm.nih.gov/14762035/
8. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170(18):1622-31. https://pubmed.ncbi.nlm.nih.gov/20937919/
9. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378(9791):584-94. https://pubmed.ncbi.nlm.nih.gov/21803414/
10. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-82. https://pubmed.ncbi.nlm.nih.gov/17544768/
11. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325-35. https://pubmed.ncbi.nlm.nih.gov/25771069/
12. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244. https://pubmed.ncbi.nlm.nih.gov/20838622/
13. Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr. 2014;100(2):657-66. https://pubmed.ncbi.nlm.nih.gov/24965307/
14. Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr. 2003;133(5):1291-5. https://pubmed.ncbi.nlm.nih.gov/12730412/
15. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003;133(12):4135-8. https://pubmed.ncbi.nlm.nih.gov/14652361/
16. Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond). 2017;14:78. https://pubmed.ncbi.nlm.nih.gov/29299040/
17. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149-60. https://pubmed.ncbi.nlm.nih.gov/23301732/
18. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007;85(1):193-200. https://pubmed.ncbi.nlm.nih.gov/17209196/
19. Wilson CP, McNulty H, Ward M, et al. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: findings of a targeted randomized trial. Hypertension. 2013;61(6):1302-8. https://pubmed.ncbi.nlm.nih.gov/23608654/
20. Wilson CP, McNulty H, Ward M, et al. Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up. Am J Clin Nutr. 2012;95(3):766-72. https://pubmed.ncbi.nlm.nih.gov/22277556/

Frequently Asked Questions